Allogeneic Cord Blood for Neurological Diseases in Adults
NCT ID: NCT05515419
Last Updated: 2025-09-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
EARLY_PHASE1
INTERVENTIONAL
2025-07-01
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for TBI
NCT05018832
Safety and Effectiveness of Banked Cord Blood or Bone Marrow Stem Cells in Children With Cerebral Palsy (CP).
NCT01988584
Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative Disorders
NCT02236065
Umbilical Cord Blood in the Treatment of Stroke in Children.
NCT01700166
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Pulmonary Diseases
NCT05147688
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Allogeneic cord blood therapy
Allogeneic cord blood therapy
Allogeneic cord blood treatment
Allogeneic cord blood treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Allogeneic cord blood treatment
Allogeneic cord blood treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Spinal cord injury (onset \< 24 months)
Exclusion Criteria
* Malignant cancer
* Renal failure
* Severe pulmonary dysfunction
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Medical Pavilion Bahamas
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Conville S Brown, MD
Role: PRINCIPAL_INVESTIGATOR
The Medical Pavilion Bahamas
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.